Open AccessMacrophages offer a paradigm switch for CNS delivery of therapeutic proteins
Author(s) -
Natalia L. Klyachko,
Matthew J. Haney,
Yanxin Zhao,
Devika S. Manickam,
Vivek Mahajan,
Poornima Suresh,
Shawn Hingtgen,
R. Lee Mosley,
Howard Eliot Gendelman,
Alexander V. Kabanov,
Elena V. Batrakova
Publication year - 2014
Publication title -
nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 109
eISSN - 1748-6963
pISSN - 1743-5889
DOI - 10.2217/nnm.13.115
Subject(s) - chemistry , drug delivery , catalase , in vivo , cytotoxicity , macrophage , cell , photothermal therapy , regeneration (biology) , biophysics , microbiology and biotechnology , nanotechnology , in vitro , oxidative stress , materials science , biochemistry , biology , organic chemistry
Active targeted transport of the nanoformulated redox enzyme, catalase, in macrophages attenuates oxidative stress and as such increases survival of dopaminergic neurons in animal models of Parkinson's disease. Optimization of the drug formulation is crucial for the successful delivery in living cells. We demonstrated earlier that packaging of catalase into a polyion complex micelle ('nanozyme') with a synthetic polyelectrolyte block copolymer protected the enzyme against degradation in macrophages and improved therapeutic outcomes. We now report the manufacture of nanozymes with superior structure and therapeutic indices.